GPX4 and bone neoplasm: The signaling pathway involving STAT3/Nrf2/GPX4 is integral to the resistance observed in osteosarcoma cells and may serve as a promising therapeutic target to improve the effectiveness of cisplatin against bone tumors (Figure 6) (191).